Actor portrayals.
TOFIDENCE is administered intravenously, with weight-based dosing and dose monitoring1
TOFIDENCE showed similar efficacy and a comparable safety profile to reference tocilizumab3,4†
Actor portrayals.
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.1
†Actemra is represented by EU-approved tocilizumab in the study. Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Adapted from: Fu et al. 2020.
TOFIDENCE binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6–mediated signaling through these receptors1
IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as RA1
Multiple clinical trials have demonstrated the efficacy of tocilizumab as monotherapy or in combination with DMARDs for adult patients with moderately to severely active RA1,3,4,7-14
FDA=US Food and Drug Administration.